Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality ([@bib19]). Of the risk factors involved in liver carcinogenesis, hepatitis B virus (HBV) chronic infection has been shown to have a major role ([@bib3]). The double-stranded DNA genome of HBV contains four overlapping open-reading frames that encode the surface protein, the core protein, a polymerase and the X protein (HBx) ([@bib14]). HBx is a multifunctional protein, which does not bind directly to DNA, but exerts transcriptional activation by its interaction with nuclear transcription factors and modulation of cytoplasmic signal transduction pathways, such as RAS/RAF/MAP signalling ([@bib15]). HBx has been demonstrated to accelerate the progress of HCC in many aspects, involving in apoptosis, proliferation, inflammation, angiogenesis, immune responses and multi-drug resistance ([@bib10]; [@bib14]; [@bib15]). Overall, an increasing body of evidence reveals the crucial role of HBx in HCC development and progress.

Other key factors that account for the aggressiveness of HCC in a poorly oxygenated microenvironment include high rates of cell proliferation and aberrant blood vessel formation ([@bib16]). The principal mechanism by which hypoxia promotes the lethal cancer phenotype is the induction of hypoxia-inducible factor-1 (HIF-1), and the expression of HIF-1 was increased in a variety of human tumors, including bladder, breast, liver, ovarian, pancreatic, prostate and renal cancers ([@bib5]; [@bib18]). HIF-1 is a heterodimeric protein that is composed of O~2~-regulated HIF-1*α* and constitutively expressed HIF-1*β* subunits ([@bib18]). Under normoxic conditions, HIF-1*α* is hydroxylated on key proline residues by proline hydroxylase domain protein 2 (PHD2), which allows for recognition by von-Hippel-Lindau protein (pVHL), the substrate recognition component of an E3 ubiquitin ligase complex that targets HIF-*α* for proteasomal degradation ([@bib4]; [@bib6]). Under the hypoxic condition, PHD2 activity is inhibited, and HIF-1*α* accumulates, translocates to the nucleus and dimerises with HIF-1*β* to form a complex capable of DNA binding at the hypoxia response elements (HREs), which controls the expression of the target proteins that have a key role in many aspects of cancer biology, such as angiogenesis, proliferation, metastasis and differentiation ([@bib18]).

The potential relationship between HBx and HIF-*α* has prompted widespread concern. Previous studies have indicated that wild-type HBx increases the level of HIF-1*α* via two mechanisms. HBx may bind directly to the bHLH/PAS domain of HIF-1*α* to inhibit the interaction between pVHL and HIF-1*α*, thus preventing degradation of HIF-1*α* protein ([@bib24]; [@bib22]). In addition, HBx can upregulate HIF-1*α* expression by stimulating metastasis-associated protein 1, histone deacetylase and the mitogen-activated protein kinase pathway ([@bib23]). It is worth noting that the HBx constructs used in all of the above studies were wild type. However, most of HBx in HCC tissues contained mutations, which may change the function of HBx. Indeed, artificial point mutations at codons 61, 69 and 137 of *HBx* have been shown to result in a marked loss of transactivation capability ([@bib8]), whereas C-terminally truncated *HBx* mutants were capable of enhancing the activation of cell proliferation and transformation ([@bib13]). As a result, although the relationship between wild-type HBx and HIF-1*α* has been investigated, the role played by naturally occurring *HBx* mutants in HIF-1*α* expression and functions has not been clearly elucidated. The aim of the study reported herein was thus to explore the possible impact of natural HBx mutants on HIF-1*α*.

Materials and methods
=====================

Patient characteristics and tissue sample collection
----------------------------------------------------

One hundred and twenty liver tumor tissues were collected from patients with HCC who underwent the surgical resection of their tumors in our hospital. All patients were tested positive for HBsAg and negative for antibodies to the hepatitis C virus (anti-HCV) and human immunodeficiency virus (anti-HIV). The study was carried out with the approval of the Chinese University of Hong Kong Ethical Committee, and the informed consent was obtained from all patients recruited.

Amplification and sequence analysis
-----------------------------------

DNA was extracted from the tissues, and *HBx* DNA was amplified by nested PCR. Gene sequencing was performed on an ABI PRISM 377TM DNA Sequencer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s instructions. More detailed information on the amplification and sequence analysis of *HBx* was presented in the [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Plasmids and site-directed mutagenesis
--------------------------------------

The wild-type *HBx* plasmid, FLAG-154X, was a kind gift from Dr M. J. Bouchard. HA 154 HBx and the mutants were constructed through amplifying the HBx sequence with primers described in [Supplementary Table S1](#sup1){ref-type="supplementary-material"} and inserting it into the vector pSG5L-HA, which encodes HA-tagged fusion protein. Site-directed mutagenesis was performed on HA 154 *HBx* using a PCR-based strategy through applying QuikChange Lightning Multi Site Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). The pcDNA-*HIF-1α* plasmid was constructed through cutting the sequence of *HIF-1α* from HA-tagged *HIF-1α*, a kind gift from Drs L. Neckers and J. S. Isaacs, and inserting it into vector pcDNA 3.1. More detailed information on the plasmids and site-directed mutagenesis was described in the [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Cell culture and reagents
-------------------------

The human hepatocarcinoma cell line, HepG2 (HB 8065), was obtained from the American Type Culture Collection and cultured in Minimum Essential Medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS). The cells were maintained at 37 °C in a humid atmosphere of 5% CO~2~. Cycloheximide (CHX) was obtained from Sigma-Aldrich (St Louis, MO, USA). The primary antibodies for HA, HBx, HIF-1*α* and *β*-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The primary antibody for Hydroxy-HIF-1*α* was purchased from Cell Signaling Technology (Danvers, MA, USA).

Western blotting and determination of HBx protein half-life
-----------------------------------------------------------

Western blotting was performed as described previously ([@bib9]). To measure the half-life of HBx protein, HepG2 cells were cultured as above, and after 24 h cycloheximide (CHX, 30 *μ*g ml^−1^) was added to the media. At indicated time points, cells were removed and protein abundance was measured by immunoblot analysis. The levels of HBx and these mutants at each time points are expressed as a percentage of their abundance at time zero.

Transient transfection and luciferase assays
--------------------------------------------

Transient transfection and luciferase assays were performed as described previously ([@bib9]).

Immunohistochemical analysis
----------------------------

Immunohistochemical analysis was performed as described previously ([@bib9]).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS version 13.0. Continuous variables were expressed as a mean with s.e. and analysed using the Student\'s *t*-test (two-tailed). Finally, a Spearman correlation analysis was carried out to determine the correlation between two rank-order variables. A *P*--value \<0.05 was considered to be statistically significant.

Results
=======

*HBx* mutations occur frequently in HCC
---------------------------------------

*HBV* DNA strands were successfully isolated and amplified by nested PCR in 101 (84.16%) cases, from a total of 120 HCC patients. The second round products of the nested PCR for HBx were purified and subjected to gene sequencing analysis. Three types of HBx mutations, including point mutations, distal carboxyl-terminal truncations and deletion mutations, were identified as shown in [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}. A total of 39 point mutation hotspots were discovered ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The top four were at nucleotides 1630, 1721, 1762 and 1764 and occurred in 51.49%, 48.51%, 53.47% and 50.50% of the 101 cases, respectively. It was particularly interested to find that mutants A1630G and G1721A always appeared concurrently and that mutant A1762T constantly accompanied mutant G1764A. As shown in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}, a total of 20 mutation hotspots of HBx proteins were identified when the codons were translated into sequences of amino acids. The dual mutations at nucleotides A1762T/G1764A affected the codons of *HBx*, resulting in a lysine to methionine change at codon 130 and a valine to isoleucine change at codon 131 (K130M/V131I). Of the double mutations A1630G/G1721A, the mutation G1721A does not lead to the alteration of *HBx* codon, and thus the double mutations affect only the codon 86 of the X protein (H86Y). In addition to these point mutations, distal C-terminal truncations have been discovered in 31.68% (32/101) of HCC cases. Deletion mutations at the C-terminus were found in three (2.97%) of them, with two cases from codon 128 to 135 and one from codon 144 to 150. It is worth noting that C-terminal truncated *HBx* was always coexistent with the full-length *HBx* with point mutations, although the truncated HBx accounted for only a smaller portion of them ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). This finding may be attributable to the mixture of both free and integrated HBV genomes in hepatocytes ([@bib2]).

Dual point mutations K130M/V131I upregulate HIF-1*α*
----------------------------------------------------

Among various *HBx* mutations, we firstly analysed several representative point mutation hotspots and created the engineered mutants through site-directed mutagenesis. To this end, six artificial HBx mutants have been established, including HA-A12T-*HBx*, HA-V44I-*HBx*, HA-A66T-*HBx*, HA-H86Y-HBx, HA-E109D-*HBx* and HA-K130M/V131I-*HBx* ([Figure 1A](#fig1){ref-type="fig"}). Equal amounts of wild-type *HBx* plasmid and the engineered mutants were transfected into HepG2 cells and confirmed by real-time PCR ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}). To define the role of *HBx* mutations on the expression of HIF-1*α*, both total and hydroxyprolin formation of HIF-1*α* were determined by western blotting with specific antibodies to each of them. It was found that their expression was increased remarkably in cells transfected with both wild-type *HBx* and mutants. Especially, the mutant HA-K130M/V131I-*HBx* induced the highest expression of them, compared with wild-type HBx and the other five *HBx* mutants ([Figure 1B](#fig1){ref-type="fig"}). No significant difference was found between the expression of total HIF-1*α* and hydroxylated HIF-1*α*. Therefore, these findings indicated that the dual point mutations A1762T/G1764A, which result in mutated K130M/V131I *HBx* proteins, enhanced the activity of HBx to regulate HIF-1*α* expression. In accordance with HIF-1*α* protein expression, there was also a remarked increase in the transcriptional activity of HIF-1*α* in HepG2 cells transfected with both wild-type HBx and the mutants. Furthermore, the mutant HA-K130M/V131I-HBx has been demonstrated to possess the ability to enhance the transcriptional activity of HIF-1*α*, compared with wild-type HBx and the other mutants (*P*\<0.05). Compared with the effects of HBx on HIF-1*α*, a similar tendency of changes in NF-*κ*B, a well defined target of HBx, was also observed ([Figure 1C](#fig1){ref-type="fig"}). The nuclear HIF-1*α* was demonstrated to be activated and the wild-type HBx was shown to induce the nuclear localization of HIF-1*α* ([@bib24]; [@bib22]). In line with these reports, we found that the expression of HIF-1*α* in the nucleus was significant higher in cells transfected with wild-type HBx ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). We further showed that the similar situation occurred in cells with HBx mutants. We next examined the effect of these mutations on themselves localization, which might have an impact on their functions. As shown in [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}, both wild-type HBx and the mutated HBx displayed a similar, predominately cytosolic localization. This finding suggested that HBx mutations remain in the cytosol in HepG2 cells. Together, these results revealed that HBx point mutants retained the functionality in upregulating the expression and activity of HIF-1*α*, and that among these HBx point mutants, HA-K130M/V131I-HBx possesses the greatest effect on HIF-1*α*.

Carboxyl-terminal truncations in HBx weaken their ability to stimulate HIF-1*α*
-------------------------------------------------------------------------------

HBV DNAs from 31.68% (32/101) of HCC cases were found with C-terminally truncated HBx. Meanwhile, HBx mutants with distal 14 amino acids or 35 amino acids deletion were discovered in the present study as well as in previous investigation ([@bib21]), suggesting that these two mutants may exist universally. We thus established two *HBx* constructs containing these two representative mutations for further experiments ([Figure 2A](#fig2){ref-type="fig"}). Equal amounts of wild-type HBx plasmid and these mutants were transfected into HepG2 cells and confirmed by real-time PCR ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}). Further studies showed that C-terminal truncations suppressed the ability of HBx to increase the expression and transcriptional activity of HIF-1*α* ([Figure 2B and C](#fig2){ref-type="fig"}). This finding is supported by an early observation in which mutants with C-terminal truncations abrogated both the antiproliferative and transactivation effects of *HBx* ([@bib13]). We further found that the length as well as the position of deletion affected the properties of *HBx*. A deletion of 14 amino acids slightly impaired the function of HBx, whereas a deletion of 35 amino acids remarkably impaired its function. In line with these results, C-terminal truncations also weakened the effect of *HBx* to promote the nuclear localization of HIF-1*α*, although these mutations did not affect the cellular localization of themselves ([Supplementary Figures S4 and S5](#sup1){ref-type="supplementary-material"}). Therefore, the region of amino acid 119 to 140 appeared to be essential for functionality of HBx. The dual point mutations K130M/V131I in this region enhanced the properties of HBx to regulate HIF-1*α*, whereas the truncations of this region abrogated this effect.

Distal C-terminal deletion mutations of *HBx* are less powerful in the upregulation of HIF-1*α*
-----------------------------------------------------------------------------------------------

Three (2.97%) of 101 HCC cases were also found with deletion mutations at the C-terminal. Of these three cases of deletion mutations, two of them (No. 6 and No. 10) generated deletions of seven amino acids from codon 128 to codon 135, and one of them (No. 93) created a reading-frame shift, leading to a deletion of the last 11 amino acids from 144. The effect of this deletion is thought to be similar to that of the C-terminal truncations, as they retain the same backbone construction. Therefore, we would like to focus on the mutants with deletion of seven amino acids from codon 128 to codon 135 of *HBx*. We isolated the natural occurring deletion mutants and cloned them into the vector of pcDNA 3.1. It is difficult to analyse the function of these deletion mutants because they coexist with some point mutations, which may interfere with the outcome. To address this issue, a full-length *HBx* fragment that contains the same point mutations as the deletion mutants was constructed and used as the control ([Figure 3A](#fig3){ref-type="fig"}). Equal amounts of wild-type *HBx* plasmid and these mutants were transfected into HepG2 cells and confirmed by real-time PCR ([Supplementary Figure S3C](#sup1){ref-type="supplementary-material"}). Because the deleted *HBx* constructs were just seven amino acids less than the full-length *HBx*, it was impossible to detect a visible change in the electrophoretic mobility with SDS-PAGE in western blotting assays ([Figure 3B](#fig3){ref-type="fig"}). We found that the mutation with deletions from codon 128 to codon 135 changed the function of *HBx* by decreasing the expression and the transcriptional activity of HIF-1*α* ([Figure 3B and C](#fig3){ref-type="fig"}). This is a novel finding as the effect of *HBx* deletion mutations on the regulation of HIF-1*α* has not been reported. Our results confirm the hypothesis that the regions of amino acid 119 to 140 are crucial for maintaining the function of *HBx*. Furthermore, we have narrowed down the critical regions of *HBx* from codon 128 to 135 in terms of their ability to regulate HIF-1*α*. Interestingly, these critical regions also contained point mutations with high frequency.

The C-terminal is essential for the stable and function of HBx
--------------------------------------------------------------

We noticed that the protein levels of HBx with C-terminal truncations or deletion mutations were obviously less than the levels of full-length *HBx*, although the same amount of HBx plasmids was transfected, as determined in the real-time PCR assays ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}). These findings may indicate that the C-terminus is essential for the stability of HBx. To further confirm this hypothesis, the half-life of HBx and its mutants were measured as described in the Materials and Methods. In brief, 24 h post transfection, cycloheximide was added to inhibit the protein synthesis and then the HBx protein was monitored by western blotting at an array of time points ([Figure 4A](#fig4){ref-type="fig"}). As our expectation, the half-life of HBx mutants with C-terminal truncation was significantly shorter than that of wild-type HBx. As shown in [Figure 4B](#fig4){ref-type="fig"}, the half-life of wild-type HBx was about 105 min, whereas that of HBx mutants HA 1--140 HBx and HA 1--119 HBx were only approximately 50 min and 35 min, respectively. Therefore, distal C-terminal truncations can impair the stability of HBx, and this finding may, at least partly, account for the reduced ability of the distal C-terminal truncation HBx in the upregulation of the expression and transcriptional activity of HIF-1*α*. Whether the C-terminal truncations could also impair the transactivational activity of HBx was another important issue to be addressed. Due to the short half-life of C-terminally truncated HBx, we thus transfected an array of amounts of these plasmids to make sure the protein levels of HBx mutants reached that of wild-type HBx. As shown in [Figure 4C and D](#fig4){ref-type="fig"}, despite the same, even more, protein levels of *HBx* mutants, the transcriptional activity of HIF-1*α* in these cells was less than that of wild-type *HBx* transfected. Therefore, in addition to the impairment of the stability, C-terminal truncations can also abrogate the HBx transactivational activity in the regulation of HIF-1*α*.

Expression of HBx protein is positively related to HIF-1*α* in HCC tissues
--------------------------------------------------------------------------

As described above, most of HBx point mutants retained the ability to upregulate HIF-1*α*, and especially the dual mutations K130M/V131I enhanced this function. C-terminal truncations and deletion mutations, however, impaired the stability and transactivation activation of HBx. As a result, the effect of HBx mutations on HIF-1*α* in a given case could be complicated because several different point mutations and/or C-terminal truncations often coexist in the same case. The overall effects of HBx mutations should be dependent on the ratio of these mutations, as schematised in [Figure 5A](#fig5){ref-type="fig"}. To confirm this inference, we determined the correlation between HBx protein and HIF-1*α* expression in HCC tissues, in which HBx mutants occurred with the mixture of these mutations. Immunohistochemical analysis was employed to determine the expression of these two proteins. The monoclonal anti-HBx antibody that was able to recognise the full-length HBx was selected so that the full-length, truncated and deleted HBx could be detected ([@bib21]). As shown in [Figure 5B](#fig5){ref-type="fig"}, the levels of HBx proteins were positively correlated with HIF-1*α* protein (*P*\<0.05). This finding suggests that despite the fact that different types of HBx mutations may possess differentiated effects toward HIF-1*α*, the overall impact of HBx mutants appear to enhance HIF-1*α*. As the HIF-1*α* protein level is an indicator of hypoxia, which promotes the progression of HCC ([@bib5]; [@bib23]; [@bib10]), we wondered whether HIF-1*α* expression was associated with patients\' prognosis. As shown in [Figure 6](#fig6){ref-type="fig"}, the expression of HIF-1*α* protein was negatively correlated with the disease-free survival rate and cumulative survival rate in this study. Taken together, our results suggest that there is a positive correlation between HBx mutants and HIF-1*α* and that an increased HIF-1*α* level signals a poor outcome for patients.

Discussion
==========

Wild-type HBx has been demonstrated to upregulate the expression and transcriptional activity of HIF-1*α* ([@bib24]), whereas the effects of HBx mutants on HIF-1*α* have not been fully elucidated. In the present studies, we thus aimed to uncover the potential relationship between HBx mutations and the activation of HIF-1*α*. Here, we revealed that the dual mutations K130M/V131I can enhance the function of HBx in upregulating HIF-1*α*. It is worth noting that these dual mutations account for approximate 50% of HCC cases in our studies and even higher incidence rate reported by others ([@bib1]). Dual mutations K130M/V131I have also been demonstrated to associate with an increased risk of HCC independent for viral loading and other risk factor ([@bib20]). Our results suggest that the enhanced function of HBx with these dual mutations in upregulating HIF-1*α* may, at least partly, contribute to the mechanism that accounts for the risk of HCC development.

The other point mutations, however, were not been shown to enhance the effect of HBx on HIF-1*α*. The underlying mechanisms accounted for the difference of the function between dual mutations K130M/V131I and other mutations may be dependent on their secondary structures and the target molecules. HBx appears to be an unstructured protein that can gain a secondary structure under specific conditions, and can be folded and acquire a specific function through its interaction with target proteins ([@bib17]). This flexibility may account for the large array of HBx activity. With the dual mutations K130M/V131I, HBx would gain more potent secondary structures to interact with HIF-1*α*, and thus increase the expression and the transcriptional activity of HIF-1*α*. Indeed, HBx mutants with dual mutations K130M/V131I have been shown to possess the increased capability of binding to p53 compared with the wild-type HBx ([@bib7]). Whether the dual mutations K130M/V131I exert more potent activity in the upregulation of HIF-1*α* than other mutations is due to its greater ability to bind to HIF-1*α* would be an important issue for further investigations. We have also noticed that no significant difference was found between the expression of total and hydroxylated HIF-1*α* induced by HBx. PHD2 promotes the formation of hydroxylated HIF-1*α*, which allows for recognition by pVHL and thus targets HIF-1*α* for proteasomal degradation ([@bib4]; [@bib6]). These results suggested that HBx might not inhibit the function of PHD2 in forming hydroxylated HIF-1*α* but suppressed the proteasomal degradation of hydroxylated HIF-1*α* through binding to them.

Carboxyl-terminal has been demonstrated to be essential for HBx to enhance the replication of HBV ([@bib12]), and C-terminal truncations of HBx decrease the transcription activation of NF-*κ*B as well as the HBV replication ([@bib11]). In accordance with these findings, we demonstrated here that C-terminal truncation of 14 and 35 amino acids impaired the function of HBx in upregulating the expression and the transcriptional activity of HIF-1*α*. This finding was also supported by the report that HBx mutants with C-terminal truncations abrogated both the antiproliferative and transactivation effects of HBx ([@bib13]). The size of the truncation at the C-terminus of HBx appeared to affect the HBx function, as the truncation of 14 amino acids (HA 1--140 HBx) only slightly inhibited the function of HBx, whereas the truncation of 35 amino acids (HA 1--119 HBx) suppressed the function of HBx tremendously. Therefore, the region of amino acids 119--140 is supposed to be essential for the function of HBx. This inference was further confirmed by the findings that HBx mutants with deletions of amino acids 128--135 also significantly abrogated the function of HBx in upregulating HIF-1*α*. Surprisingly, we have also noticed that the expression of HBx mutants with C-terminal truncations or deletion mutations was significantly less than that of wild-type HBx, although the same amount of plasmids were used. Further studies demonstrated that C-terminal truncation of 14 and 35 amino acids decreased the half-life of HBx from 105 min to 50 min and 35 min, respectively. This tendency was consistent with previous report showing that the half-life of 1--131 HBx and 1--140 HBx was less than the wild-type HBx ([@bib11]). The decreased stability of the truncated HBx mutants suggested that we had to overcome decreased protein levels of HBx mutants to test the functionality of the C-terminal truncated HBx mutants. This was accomplished by increasing the amounts of transfected C-terminal truncation plasmids relative to the wild-type HBx plasmid. Although the truncated HBx mutants were expressed at levels that were similar to or greater than the level of wild-type HBx, neither HA 1--140 HBx nor HA 1--119 HBx could stimulate HIF-1*α* transcriptional activity to the level achieved by wild-type HBx. Therefore, the C-terminus, especially the region of amino acids 119--140, appears to be essential for the stability and the transactivation of HBx. Truncations or deletions of C-terminus may disrupt the structure of HBx, leading to degradation and impairment of their capability in interacting with target proteins.

Altogether, most of *HBx* point mutants retained the ability to upregulate HIF-1*α*, and especially the dual mutations K130M/V131I enhanced this function. C-terminal truncations and deletion mutations, however, impaired the stability and transactivation activation of HBx. It is noted that the *HBx* mutants with point mutations and the mutants with C-terminal truncation or deletion frequently coexist in the same HCC case. Therefore, the overall effect of *HBx* mutants in HCC should depend on the ratio of these mutants. In line with this inference, the level of total HBx protein is positively correlated with the expression of HIF-1*α* in the HCC tissue samples that contain various types of HBx mutants, and thus the effect of naturally occurring *HBx* mutants may dominantly upregulate HIF-1*α*. Indeed, it has been noted that in HBV-positive cells only a small amount of HBx is found, whereas transfected cells would gain strong overexpression of HBx protein, although a small amount of plasmids was used in our experiments. Further investigations should focus on the establishment of HBx expression systems that can be used to mimic the natural HBV infection in HCC cells.

In conclusion, the carboxyl-terminus, especially amino acids 119--140, is essential for the stability and transactivation of HBx. The dual point mutations K130M/V131I in this region result in enhanced functionality of HBx, whereas mutations of C-terminal truncation or deletion may weaken the function of HBx in upregulating HIF-1*α*. However, the overall function of HBx in a given case appears to enhance HIF-1*α,* as the protein levels of HBx are positively correlated with the expression of HIF-1*α* in HCC tissues containing various types of HBx mutants.
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![**The effect of HBx point mutations on HIF-1*α*.** (**A**) Schematic of the full-length *HBx* and HBx point mutations used in this study. The vertical bars in orange indicated the position of mutations (**B**) HepG2 cells were transfected with the indicated plasmids. After 24 h transfection, the expression of protein was detected by western blot analysis (WB) with indicated antibodies. (**C**) HepG2 cells were cotransfected with the indicated plasmids and the luciferase reporter gene constructs pBI-GL (vector), pBI-GL-V6L and pBI-GL-NF-*κ*B. After 24 h transfection, the activity was detected by luciferase assays. The error bars represent s.e. \* indicates *P*\<0.05, compared with HA or HA 154 *HBx* plasmids transfected groups. The experiments were repeated three times with similar results.](bjc2013787f1){#fig1}

![**C-terminal truncations inhibit the expression and transcriptional activity of HIF-1*α*.** (**A**) Schematic of the full-length *HBx* and mutants with C-terminal truncations created for this study. (**B**) HepG2 cells were transfected with the indicated plasmids. After 24 h transfection, the expression of protein was detected by WB with indicated antibodies. (**C**) HepG2 cells were cotransfected with the indicated plasmids and the luciferase reporter gene constructs pBI-GL (vector), pBI-GL-V6L and pBI-GL-NF-*κ*B. After 24 h transfection, the activity was detected by luciferase assays. The error bars represent s.e. \* indicates *P*\<0.05. The experiments were repeated three times with similar results.](bjc2013787f2){#fig2}

![**C-terminal deletion mutations decreased the expression and the transcriptional activity of HIF-1*α*.** (**A**) Schematic of wild-type full-length HBx (wt 154 HBx) or full-length HBx containing point mutations (mt 154 HBx), and the mutants with C-terminal deletions (deleted HBx) created for this study. (**B**) HepG2 cells were transfected with the indicated plasmids. After 24 h transfection, the expression of protein was detected by western blot analysis (WB) with indicated antibodies. (**C**) HepG2 cells were cotransfected with the indicated HBx plasmids and the luciferase reporter gene constructs, pBI-GL (vector), pBI-GL-V6L and pBI-GL-NF-*κ*B. After 24 h transfection, the activity was detected by luciferase assays. The error bars represent s.e. \* indicates *P*\<0.05. The experiments were repeated three times with similar results.](bjc2013787f3){#fig3}

![**C-terminal truncations lead to the decreased half-life and transactivation activity of HBx.** (**A**) HepG2 cells in six-wells plates at 80% confluenc were transfected with 0.5 *μ*g HA 154 HBx, 1 *μ*g HA 1--140 HBx and 3 *μ*g HA 1--119 HBx constructs. After 24 h transfection, cycloheximide (CHX, 30 *μ*g ml^−1^) was added to the medium to inhibit protein synthesis, and then the HBx protein was monitored by western blotting with an anti-HA antibody at the indicated time points. (**B**) The schematic illustration shows the densitometric quantification of the results in which the expression of HA 154 HBx, HA 1--140 HBx, or HA 1--119 HBx at time zero was set as 100%. The expression levels of these mutants at subsequent time points are expressed as a percentage of the levels of each relative to their expression at time zero. The error bars represent s.e. (**C**) HepG2 cells were cotransfected with the luciferase reporter gene constructs, pBI-GL-V6L, and an array of amounts of the indicated HBx plasmids. After 24 h transfection, the activity was detected by luciferase assays. The error bars represent s.e. (**D**) The protein levels of HBx of these samples were detected via western blotting analysis with an anti-HA antibody. The experiments were repeated three times with similar results.](bjc2013787f4){#fig4}

![**Expression of HBx protein is positively related to HIF-1*α* in HCC tissues.** (**A**) Schematic illustration shows the different effects of HBx mutations on the regulation of HIF-1*α*. Although most of point mutations in HBx did not affect their ability to regulate HIF-1*α*, dual mutations K130M/V131I enhanced HBx ability to upregulate HIF-1*α*, whereas C-terminal truncations and deletion mutations reduced their ability to stimulate HIF-1*α*. The overall effects of HBx mutants on HIF-1*α* depend on the balance of these mutations. (**B**) The protein levels of HBx and HIF-1*α* were detected by immunohistochemical analysis (upper panel), and the relationship between them was determined by Spearman\'s rank correlation analysis (lower panel). The experiments were repeated three times with similar results.](bjc2013787f5){#fig5}

![**The levels of HIF-1*α* protein in HCC tissues are correlated with poor outcomes of HCC patients.** The protein levels of HIF-1*α* were detected by ELISA and the Kaplan--Meier survival analysis was carried out to determine the overall survival rate and disease-free survival rate. The difference between the HIF-1*α* \<250 ng ml^−1^ group and the HIF-1*α* \>250 ng ml^−1^ group was significant in both the disease-free survival rate and cumulative survival rate.](bjc2013787f6){#fig6}
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